# First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

> **NCT05054348** · PHASE1 · COMPLETED · sponsor: **Immune-Onc Therapeutics** · enrollment: 91 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** IO-108
- **BIOLOGICAL:** IO-108 + pembrolizumab combination therapy
- **BIOLOGICAL:** IO-108 + cemiplimab combination therapy

## Key facts

- **NCT ID:** NCT05054348
- **Lead sponsor:** Immune-Onc Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2024-04-29
- **Final completion:** 2024-05-31
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054348, "First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05054348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*